AI empowers intelligent monitoring, breakthroughs in biomaterials, S&P Biotech ETF China Harvest rises 2.08%

K-LinePoet · 2026-04-01T03:11:03+00:00

As of March 5th, the Shanghai Composite Index increased by 0.78%, and the ChiNext Index rose by 2.41%. The medical devices industry is facing opportunities and challenges, and the white paper explores the integration of technological advancements and health care. Gaoshi Medical will celebrate its two-year anniversary of going public, and an exclusive interview with its CEO will discuss strategic transformations.

K-LinePoet

2026-04-01 03:11:03

Abstract generation in progress

As of 10:48 on March 5, the Shanghai Composite Index increased by 0.78%, the Shenzhen Component Index rose by 1.63%, and the ChiNext Index gained 2.41%. Leading gains were seen in sectors such as the MicroLED concept, optical and optoelectronics, and electronic paper.

In terms of ETFs, the SPDR S&P Biotech ETF managed by Harvest (159502) increased by 2.08%. The constituent stocks Day One and Gossamer Bio rose by over 20%. Moderna (MRNA.US), AnaptysBio (ANAB.US), Iovance (IOVA.US), Dianthus (DNTH.US), and Arrivent (AVBP.US) each rose by more than 10%. Tango Therapeutics, Vir Biotechnology, and Erasca (ERAS.US) each increased by over 5%.

The Shanghai Federation of Modern Service Industries stated that the wave of life sciences is surging forward, and the medical device industry has always been a core force supporting health. This white paper examines the industry’s growth trajectory amid policy updates, technological advancements, and global supply chain changes—from cutting-edge equipment for precise diagnosis and treatment to medical devices that serve grassroots healthcare; from AI-powered intelligent monitoring to breakthroughs in biomaterials. We aim to analyze challenges from a professional perspective and to anchor the future with forward-looking thinking—so that every technological breakthrough leads to more compassionate medical care, and every industry advancement becomes a solid step in safeguarding lives.

iResearch (Hurun Research Institute) indicated that China’s 2024 government work report prioritizes developing “new productive forces,” bringing new opportunities and challenges to the ophthalmic medical device industry. On December 12, 2024, HighTech Medical celebrated its second anniversary since listing. Fosun Sullivan conducted an interview with the company’s CEO, Mr. Liu Xinwei, to explore HighTech Medical’s strategic transformations amid opportunities across different eras.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.